The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Highly Bioavailable Curcumin Derivative Ameliorates Crohn’s Disease Symptoms: A Randomized, Double-Blind, Multicenter Study
Abstract
Background & Aims: The new curcumin derivative Theracurmin® has a 27–fold higher absorption rate than natural curcumin powder. Theracurmin® is an inhibitor of nuclear factor-κB, which mediates the expression of inflammatory cytokines. The effect of Theracurmin® on inflammatory bowel disease in humans has not been explored; therefore, we investigated the efficacy and safety of Theracurmin® in patients with Crohn’s disease. Methods: In this randomized, double-blinded study performed at 5 independent medical centers in Japan, Theracurmin® (360 mg/day, n = 20) or placebo (n = 10) was administered to patients with active mild-to-moderate Crohn’s disease for 12 weeks. The agent’s efficacy was assessed by evaluating clinical and endoscopic remission, healing of anal lesions, and blood levels of inflammatory markers. Results: In the Theracurmin® group, a significant reduction in clinical disease activity was observed in week 12 relative to that in week 0 (p = 0.005). On intention-to-treat analysis, clinical remission rates were 35%, 40%, and 40% at weeks 4, 8, and 12, respectively, which were significantly higher than those in the placebo group (all 0%; p = 0.033, p = 0.020, and p = 0.020, respectively). Furthermore, reduction in endoscopic Crohn’s disease severity (p = 0.032) was observed at week 12 in the Theracurmin® group. The endoscopic remission rates were 15% and 0% in the Theracurmin® and placebo groups, respectively. Significant healing of anal lesions (p = 0.017) was observed at week 8 in the Theracurmin® group. No serious adverse events were observed in either group throughout the study. Conclusions: Theracurmin® shows significant clinical and endoscopic efficacy together with a favorable safety profile in patients with active mild-to-moderate Crohn’s disease. Clinical trial UMIN registration ID: UMIN000015770.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies with small sample sizes and zero events demonstrated reduced precision of estimates of treatment effect (Lang et al., 2015;Sugimoto et al., 2020).”
From A systematic review of the efficacy and safety of turmeric in the treatment of digestive disorders (2024) · cites this paper as Sugimoto et al., 2020
In the citing paper
“Patients included in the two studies of CD had either (1) been treated with thiopurines and had a recent surgical resection and anastomosis (Bommelaer et al., 2020) or (2) been definitively diagnosed with CD based on radiologic, endoscopic, and histologic criteria (Sugimoto et al., 2020).”
From A systematic review of the efficacy and safety of turmeric in the treatment of digestive disorders (2024) · cites this paper as Sugimoto et al., 2020
In the citing paper
“Patients were excluded if they used treatments not allowed or covered under the Japanese medical insurance system, such as >3 g/day of mesalamine or some monoclonal antibodies.”
From A systematic review of the efficacy and safety of turmeric in the treatment of digestive disorders (2024) · cites this paper as Sugimoto et al., 2020
In the citing paper
“For example, Sugimoto et al. conducted a curcumin trial with CD patients in Japan (Sugimoto et al., 2020).”
From A systematic review of the efficacy and safety of turmeric in the treatment of digestive disorders (2024) · cites this paper as Sugimoto et al., 2020
In the citing paper
“Of the nine included studies that focused on IBD, only a single study by Sugimoto et al. (Sugimoto et al., 2020) reported at least one outcome measure from the COS at a follow-up time recommended for induction trials (Ma et al., 2022).”
From A systematic review of the efficacy and safety of turmeric in the treatment of digestive disorders (2024) · cites this paper as Sugimoto et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins
Veldhoen, M., Hirota, K., Westendorf, A. M., Buer, J., Dumoutier, L., Renauld, J.-C., & Stockinger, B. (2008) · Nature · doi:10.1038/nature06881 · Cited by 1,634
Research works printed but not linked: 28
- Baumgart, 2012, Crohn’s disease, Lancet, 380, 1590, 10.1016/S0140-6736(12)60026-9 · DOI
- Hanauer, 2002, Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial, Lancet, 359, 1541, 10.1016/S0140-6736(02)08512-4 · DOI
- Colombel, 2007, Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial, Gastroenterology, 132, 52, 10.1053/j.gastro.2006.11.041 · DOI
- Sandborn, 2012, Ustekinumab induction and maintenance therapy in refractory Crohn’s disease, N Engl J Med, 367, 1519, 10.1056/NEJMoa1203572 · DOI
- Govindarajan, 1980, Turmeric–chemistry, technology, and quality, Crit Rev Food Sci Nutr, 12, 199, 10.1080/10408398009527278 · DOI · Paper page
- Jobin, 1999, Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity, J Immunol, 163, 3474, 10.4049/jimmunol.163.6.3474 · DOI
- Hanai, 2009, Curcumin has bright prospects for the treatment of inflammatory bowel disease, Curr Pharm Des, 15, 2087, 10.2174/138161209788489177 · DOI
- Sugimoto, 2002, Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice, Gastroenterology, 123, 1912, 10.1053/gast.2002.37050 · DOI · Paper page
- Ali, 2012, Curcumin and inflammatory bowel disease: biological mechanisms and clinical implication, Digestion, 85, 249, 10.1159/000336720 · DOI
- Hanai, 2006, Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial, Clin Gastroenterol Hepatol, 4, 1502, 10.1016/j.cgh.2006.08.008 · DOI · Paper page
- Singla, 2014, Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis - a randomized, placebo-controlled, pilot study, J Crohns Colitis, 8, 208, 10.1016/j.crohns.2013.08.006 · DOI
- Lang, 2015, Curcumin in combination with mesalamine induces remission in patients with mild-to-moderate ulcerative colitis in a randomized controlled trial, Clin Gastroenterol Hepatol, 13, 1444, 10.1016/j.cgh.2015.02.019 · DOI · Paper page
- Sasaki, 2011, Innovative preparation of curcumin for improved oral bioavailability, Biol Pharm Bull, 34, 660, 10.1248/bpb.34.660 · DOI · Paper page
- Dei Cas, 2019, Dietary curcumin: correlation between bioavailability and health potential, Nutrients, 11, E2147, 10.3390/nu11092147 · DOI
- Ohno, 2017, Nanoparticle curcumin ameliorates experimental colitis via modulation of gut microbiota and induction of regulatory T cells, PLoS One, 12, e0185999, 10.1371/journal.pone.0185999 · DOI
- Lyakhovich, 2010, Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine, Aliment Pharmacol Ther, 31, 202, 10.1111/j.1365-2036.2009.04195.x · DOI
- Zhang, 2016, Protective effect of curcumin on TNBS-induced intestinal inflammation is mediated through the JAK/STAT pathway, BMC Complement Altern Med, 16, 299, 10.1186/s12906-016-1273-z · DOI
- van Ede, 2008, Bioassay directed identification of natural aryl hydrocarbon-receptor agonists in marmalade, Anal Chim Acta, 617, 238, 10.1016/j.aca.2008.01.054 · DOI
- Sugimoto, 2008, IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis, J Clin Invest, 118, 534
- Lehmann, 2015, The role and utility of faecal markers in inflammatory bowel disease, Therap Adv Gastroenterol, 8, 23, 10.1177/1756283X14553384 · DOI
- Yang, 2007, Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS, J Chromatogr B Analyt Technol Biomed Life Sci, 853, 183, 10.1016/j.jchromb.2007.03.010 · DOI
- Kanai, 2012, Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers, Cancer Chemother Pharmacol, 69, 65, 10.1007/s00280-011-1673-1 · DOI
- Kanai, 2013, A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients, Cancer Chemother Pharmacol, 71, 1521, 10.1007/s00280-013-2151-8 · DOI
- Sunagawa, 2015, Colloidal submicron-particle curcumin exhibits high absorption efficiency-a double-blind, 3-way crossover study, J Nutr Sci Vitaminol (Tokyo), 61, 37, 10.3177/jnsv.61.37 · DOI
- Shin, 2017, Short-term effects of Theracurmin dose and exercise type on pain, walking ability, and muscle function in patients with knee osteoarthritis, J Exerc Rehabil, 13, 684, 10.12965/jer.1735064.532 · DOI
- Lacruz-Guzmán, 2013, Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn’s disease and ulcerative colitis, Eur J Clin Pharmacol, 69, 431, 10.1007/s00228-012-1389-0 · DOI
- Gupta, 2013, Therapeutic roles of curcumin: lessons learned from clinical trials, AAPS J, 15, 195, 10.1208/s12248-012-9432-8 · DOI · Paper page
- Schneider, 2017, Comparison of remicade to curcumin for the treatment of Crohn’s disease: A systematic review, Complement Ther Med, 33, 32, 10.1016/j.ctim.2017.06.002 · DOI
Cited by
A systematic review of the efficacy and safety of turmeric in the treatment of digestive disorders
Thavorn, K., Wolfe, D., Faust, L., Shorr, R., Akkawi, M., Isaranuwatchai, W., Klinger, C., Chai‐Adisaksopa, C., Tanvejsilp, P., Nochaiwong, S., et al. (2024) · Phytotherapy Research · doi:10.1002/ptr.8189 · Cited by 11
Metadata
- Authors
- Sugimoto, K., Ikeya, K., Bamba, S., Andoh, A., Yamasaki, H., Mitsuyama, K., Nasuno, M., Tanaka, H., Matsuura, A., Kato, M., Ishida, N., Tamura, S., Takano, R., Tani, S., Osawa, S., Nishihira, J., & Hanai, H.
- Affiliations
- The First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
- Centre for Gastroenterology & IBD Research, Hamamatsu South Hospital, Hamamatsu, Japan
- Division of Clinical Nutrition, Shiga University of Medical Science, Otsu, Japan
- Division of Gastroenterology, Shiga University of Medical Science, Otsu, Japan
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan
- Inflammatory Bowel Disease Centre, Kurume University School of Medicine, Kurume, Japan
- IBD Centre, Sapporo Kosei General Hospital, Sapporo, Japan
- Department of Endoscopic and Photodynamic Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
- Department of Medical Management and Informatics, Hokkaido Information University, Ebetsu, Japan
- ORCID
- Bamba, Shigeki
- Venue
- Journal of Crohn's and Colitis
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-05-15
- Volume
- 14
- Issue
- 12
- Pages
- 1693-1701
- ISSN
- 1873-9946
- 1876-4479
- Cited by
- 63
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
